Basilea Pharmaceutica's second-quarter 2008 net loss widened 5.4% to 67.9 million Swiss francs ($66.6 million), or a loss of 7.11 francs per basic and diluted share. The biopharmaceutical firm, based in Basel, Switzerland, saw revenues increase 62.5% to 5.2 million francs.
Lehman Brothers analyst Peter Welford said that the losses were broadly in-line with estimates. He noted that the 177% increase in the firm's general and administrative expenses, to 29.4 million francs, was more than expected. However, this is a positive as the ramp up for commercialization of its two products aliretinoin and predicted blockbuster ceftobiprole is taking place earlier than forecast - within the next six to nine month - suggesting that management is confident of approvals. Co-developed with Johnson & Johnson, he expects ceftobiprole to be approved in Europe for complicated skin and skin structure infections in fourth-quarter 2008 and in the USA during first-quarter 2009.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze